16th & 17th NovemberManchester, UK

Innovation Sponsor

Online Market Place for R&D Outsourcing

Description: By enabling scientists to easily Outsource Everything but the Genius®, we are pioneering a faster, leaner and more innovation-centric approach to research. Our vision is to create a world in which scientists are limited only by their imagination.

Welcome

...to Biotech Outsourcing Strategies Manchester 2022

Launched in 2006 by Bio2Business Ltd, the Biotech Outsourcing Strategies Events bring together stakeholders in R&D outsourcing to share experience, build existing outsourcing partnerships and forge new buyer/supplier business relationships. The established BOS Formula is built on 4 key pillars; Exhibition showcasing international CROs and CMOs; High Quality Content (delivered through the multi-stream programme); 1-to-1 Partnering; Informal Networking (BOS Events are known for being friendly, intimate events, which create the perfect conditions for networking!).

We are delighted to bring the BOS Events to the north of England and to a city synonymous with industrial and technological progression. BOS Manchester 2022 will cover Discovery Outsourcing, Small Molecule CMC Outsourcing and Biologics CMC Outsourcing. We look forward to welcoming you to the events new home in the heart of Manchester.

Resources for Sponsors & Attendees

Our valued sponsors can access our Getting started with your BOS Manchester Sponsorship - Step-by-step Guide. In addition, sponsors can refer to a summary of the Exhibition Logistics. Book your accommodation at BOS Manchester 2022 by clicking here.

Covid restrictions were lifted in the United Kingdom in early 2022.

Featured Speaker (BOS Manchester 2022)

Hurdles to Develop a Parenteral Nanosuspension Formulation for Early Clinical Phase

Dr Yogeshwar Bachhav, Associate Director (Consultant), AiCuris Anti-infective Cures AG

ABSTRACT: Majority of the NCEs display a poor solubility in aqueous environment and this presents a great deal of challenge to deliver the active at the site of action. The issue of poor solubility is also leads to the poor efficacy and failure of the compound to succeed the cycle of drug development.
It’s important to initiate the development of enabled formulations such as nanosuspensions at early stage so that sufficient exposures can be attained in the preclinical safety studies. Also, time required to optimize the Frist in human (FIH) formulation can be gained.
The current talk will... Click here to Read More

Featured Company (BOS Manchester 2022)

DIPHARMA FRANCIS
Dipharma Group is a global CDMO and a leading manufacturer of Active Pharmaceutical Ingredients and Intermediates. As part of the global pharmaceutical industry, we serve human health and, therefore, operate to the highest standards of quality and safety with proven experience in handling complex and...
View profile